{"id":"W2137551916","doi":"10.1158/1078-0432.ccr-05-2215","title":"Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"ca_institutions":"Immunovaccine (Canada)","funders":"National Center for Research Resources; National Institute of Neurological Disorders and Stroke; National Cancer Institute","keywords":"Gefitinib; Medicine; Sirolimus; Rash; Mucositis; Pharmacology; Dosing; Internal medicine; Glioma; Chemotherapy; Tyrosine-kinase inhibitor; Anaplastic astrocytoma; Epidermal growth factor receptor; Oncology; Gastroenterology; Cancer; Cancer research; Astrocytoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001182305,0.001717443,0.00214404,0.0003725393,0.0003692498,0.0006247432,0.0007250897,0.001000108,0.002142182],"category_scores_gemma":[0.0009448018,0.0004784377,0.0009850637,0.000302881,0.0005573924,0.0005561546,0.0003037569,0.002202075,0.0006683609],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001176021,"about_ca_system_score_gemma":0.001666053,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001265501,"about_ca_topic_score_gemma":0.003928322,"domain_scores_codex":[0.9995516,0.0002027249,0.0000357726,0.00008603304,0.00005182806,0.00007203469],"domain_scores_gemma":[0.9994382,0.00006515392,0.000163376,0.00003195118,0.00004148531,0.0002598835],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7730575,0.03264664,0.01525315,0.0009478759,0.002404166,0.0004685544,0.0004450331,0.002768086,0.03426973,0.000187943,0.004523236,0.133028],"study_design_scores_gemma":[0.511542,0.4483667,0.02974361,0.00003636058,0.0008403604,0.0006788508,0.00006747371,0.001955792,0.003520124,0.000128858,0.003080697,0.00003922027],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957926,0.001652493,0.0002560414,0.0003382427,0.00006345471,0.0009647815,0.0003319954,0.00006994631,0.0005302737],"genre_scores_gemma":[0.9950424,0.0009697528,0.0008193128,0.00045211,0.0001398673,0.0009437367,0.0008446659,0.00001461905,0.0007735548],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00214404,"threshold_uncertainty_score":0.008532643,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1872098037025844,"score_gpt":0.5209507669304803,"score_spread":0.3337409632278959,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}